News and Announcements
Kazia Therapeutics CEO featured in the Australian Financial Review
- Published August 20, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia’s Therapeutics Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.
In the interview, Dr Garner spoke about the importance of networks and collaborations in the biotech industry and how Kazia focuses on structuring and managing the approvals and trial stages of drug development.
The article also talks about the five ongoing trials with Kazia’s lead candidate, GDC-0084 and our recent announcement that leading US cancer treatment centre, Memorial Sloan Kettering (MSK), will use GDC-0084 in a phase I clinical trial for cancer that has spread to the brain (brain metastases).
Read the article here.
Interview with Proactive Investors
Also recently, Dr Garner also discussed the ongoing clinical program with GDC-0084 and the completion of recruitment for Part B of the Cantrixil trial in an interview with Proactive Investors.
In the interview, Dr Garner also discusses:
• Kazia’s strategy with GDC-0084
• How equity market volatility impacts Kazia
• The upcoming milestones and value catalysts for the company
Watch the video interview here.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
